August 19, 2025 4:41pm

Share pricing sprinted-up the sector mountain, then had to crawl-down

As my covered sector’s Advance/Decline (A/D) line dived Tuesday to 5/28 and 2 flats from Monday’s 18/17 and 0 flats following Friday’s 25/9 and 1 flat

My “posts” are conveyed with a simplicity of language to highlight what is informative.

Never leave an investor uninformed!  

“When you’re riding’ ahead of the sector herd, take a look back every now and then to make sure your share pricing “cows” are moving

As the leading voice of cell and gene therapy investors; it’s hard to be right so often, it’s about defining insight with hours, days, months and years of experience.

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in their portfolio for the short-term

 

Tuesday’s RegMed Investors’ (RMi) pre-open: Flat lining after eking-out gains … https://www.regmedinvestors.com/articles/14069

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The Dow closed UP +10.45 points or +0.02%, the S&P closed DOWN -37.78 points or -0.59% while the Nasdaq closed DOWN – 314.82 points or -1.46%

  • Theme of the session, awaiting Jerome’s whispers and retail earnings releases

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • A mixed bag for the struggling U.S. housing market: Privately owned starts totaled a seasonally adjusted annual rate of 1.428 M, up 5.2% from the upwardly revised June figure and well above the consensus estimate for 1.29 M. For building permits, though, the total of 1.354 M was 2.8% off the June pace and less than the 1.39 M estimate. Housing completions totaled 1.415 M, a 6% increase from the prior month. Units under construction were little changed monthly at 1.36 M though down 12.4% from a year ago.

Tuesday’s advance/decline line opened negative with 10 incliners, 20 decliners and 5 flats ending with a negative close of 5 incliners, 28 decliners and 2 flats

Metrics:  Tuesday, the IBB was down -0.49%, the XBI was down -1.41% while the VIX was up +0.58 points or +3.87% at 15.57

 

Q3 – August – 7 negative and 6 positive closes

  • July – 1 market holiday, 13 positive and 9 negative closes

Q2/25: June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes, May – 1 market holiday, 10 negative and 11 positive closes and April – 11 positive and 10 negative closes

 

Tuesday Closing UP (5 of 5) 

  • Alnylam Pharmaceuticals (ALNY +$1.41 after Monday’s +$7.96),
  • Precigen (PGEN +$0.27),
  • Cellectis SA (CLLS +$0.08),
  • Brainstorm Cell Therapeutics (BCLI +$0.04),
  • BioLife Solutions (BLFS +$0.04 after Monday’s +$0.16),

Flat (2)

  • Adverum Biotechnologies (ADVM)
  • MiMedx (MDXG

Tuesday’s Closing DOWN (10 of 28): 

  • CRISPR Therapeutics (CRSP -$3.43 after Monday’s -$2.14),
  • Lenz Therapeutics (LENZ -$1.16 after Monday’s +$0.92),
  • BioNTech SE (BNTX -$1.15 after Monday’s -$0.97),
  • Supernus Therapeutics (SUPN -$0.99 after Monday’s +$0.30),
  • Ionis Pharmaceuticals (IONS -$0.95 after Monday’s -$0.35),
  • Sarepta Therapeutics (SRPT -$0.81 after Monday’s -$0.82),
  • Mesoblast (MESO -$0.79 after Monday’s -$0.32),
  • Beam Therapeutics (BEAM -$0.75 after Monday’s -$0.72),
  • Regenxbio (RGNX -$0.68),
  • Ultragenyx Pharmaceuticals (RARE -$0.58),

 

The BOTTOM LINE:  Disappointing share pricing download yet, expected … as I had written, ““Uncle algo and his electronic trading dwarfs” are in the house”

Meanwhile, Q2 earnings season is winding down, tks!

On the Nasdaq, remained the weakest of the major indexes and sank 1.5% also falling stocks edged out rising ones by more than 7-to-4.

  • Small caps on the Russell 2000 also continued to weaken, falling 0.8%.
  • Volume was higher on the Nasdaq compared with Monday.

Meanwhile, President Trump continued to press for further Ukraine talks, reportedly asking Russian President Putin to meet with Volodymyr Zelensky.

  • European leaders rallied around the Ukrainian president at his meeting with Trump on Monday, but markets hit pause as uncertainty loomed over his country's fate. <Yahoo Finance>

Reiterating, the market had braced for a historically weak month … August is the worst month for the Dow in data going back to 1988, and the 2nd worst for the S&P 500 and Nasdaq according to the Stock Trader’s Almanac.

 

When Fed Chair Powell gives his last speech in Jackson Hole, Wyo., this Friday, investors will be listening for whether he signals an interest rate cut next month. <some from Yahoo, answers … from me!>

  • But Powell … could lay out more overarching changes to the central bank’s dual mandate that will last long after his tenure is up next May — and mark part of his legacy.
  • I Doubt it, he will have NO legacy!
  • Powell will share his outlook for the economy at Jackson Hole.
  • But he is also expected to lay out changes to the central bank’s policy framework review, which articulates the Fed’s strategy and commitment to fulfilling its congressional mandate for stable prices and maximum employment.
  • His words and strategy will be scrapped …
  • In particular the central bank is expected to drop so-called average inflation targeting, a policy put in place pre-pandemic when inflation was running low and Fed officials wanted to avoid deflation.
  • Forget about it!
  • Bottom line … CUT the rates, Powell will be gone if he doesn’t and the new head will determine the future role of the FED!!
  • Read my words …!!

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

Earnings today: None

  • As earnings slowly come to the last few releases, collaborator revenues and runways has instilled share pricing with forward stability
  • Q2 results so far:  4 net incomes and 25 net losses of 29 releases to date

 

August begins as July ends: understand the “flow” …

  • 8/19 - Tuesday closed negative with 5 positive, 28 negative and 2 flats
  • 8/18 -Monday closed neutral with 18 positive, 17 negative and 0 flat
  • 8/15 – Friday - closed positive with 25 positive, 9 negative and 1 flat
  • 8/14 – Thursday closed barely positive with 18 positive, 17 negative and 0 flat
  • 8/13 – Wednesday closed positive with 32 positive, 2 negative and 1 flat
  • 8/12 - Tuesday closed positive with 28 positive, 6 negative and 1 flat
  • 8/11 – Monday closed negative with 10 positive, 25 negative and 0 flat
  • 8/8 – Friday closed negative with 11 positive, 23 negative and 1 flat
  • 8/7 – Thursday closed negative with 9 positive, 24 negative and 2 flats
  • 8/6 - Wednesday closed negative with 11 positive, 22 negative and 2 flats
  • 8/5 – Tuesday closed negative with 15 positive, 19 negative and 1 flat
  • 8/4 – Monday closed positive with 27 positive, 8 negative and 0 flat
  • 8/1 – Friday closed negative with 9 positive, 20 negative and 6 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Tuesday: Alnylam Pharmaceuticals (ALNY), Precigen (PGEN) and Cellectis SA (CLLS)
  • Monday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Lenz Pharmaceuticals (LENZ)
  • Friday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Sarepta Therapeutics (SRPT)

The worst three (3) in the session: 

  • Tuesday: CRISPR Therapeutics (CRSP), Lenz Pharmaceuticals (LENZ) and BioNTech (BNTX)
  • Monday: CRISPR Therapeutics (CRSP), BioNTech (BNTX) and Sarepta Therapeutics (SRPT)
  • Friday: Lenz Pharmaceuticals (LENZ), BioLife Solutions (BLFS) and Generation Bio (GBIO)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.